Combinations of 2′-C-methylcytidine analogues with interferon-α2b and triple combination with ribavirin in the hepatitis C virus replicon system

Antiviral Chemistry and Chemotherapy

Volumn 19, Issue 1, 2008, Pages 25-31

  Bassit, Leda ^a   Grier, Jason ^a   Bennett, Matthew ^a   Schinazi, Raymond F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEXTRO 2' C METHYLCYTIDINE; BETA DEXTRO 2' DEOXY 2' FLUORO 2' C METHYLCYTIDINE; NM 107; PSI 6130; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RIBOSOME RNA; 2' C METHYLCYTIDINE; 2' DEOXY 2' FLUORO 2' C METHYLCYTIDINE; 2'-C-METHYLCYTIDINE; 2'-DEOXY-2'-FLUORO-2'-C-METHYLCYTIDINE; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CYTIDINE; DEOXYCYTIDINE; DRUG DERIVATIVE; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; COMPUTER SIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPLICON; RNA EXTRACTION; VIRUS REPLICATION; CELL CULTURE; CHEMICAL MODEL; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; MONTE CARLO METHOD; POLYMERASE CHAIN REACTION;

ANTIVIRAL AGENTS; CELLS, CULTURED; COMPUTER SIMULATION; CYTIDINE; DEOXYCYTIDINE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HUMANS; INTERFERON ALFA-2B; MODELS, CHEMICAL; MONTE CARLO METHOD; POLYMERASE CHAIN REACTION; REPLICON; RIBAVIRIN; RNA, RIBOSOMAL; RNA, VIRAL;

EID: 47049112231     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020801900104     Document Type: Article

References (31)

1. Abergel A, Hezode C, Leroy V, et al. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b. J Viral Hepat 2006; 13:811-820.
2. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2a plus ribavirin. Gastroenterology 2006; 131:1040-1048.
3. Carroll SS, Olsen DB. Nucleoside analogue inhibitors of hepatitis C virus replication. Infect Disord Drug Targets 2006; 6:17-29.
4. Pierra C, Benzaria S, Amador A, et al. NM 283, an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. Nucleosides Nucleotides Nucleic Acids 2005; 24:767-770.
5. Pierra C, Amador A, Benzaria S, et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. J Med Chem 2006; 49:6614-6620.
6. Toniutto P, Fabris C, Bitetto D, Fornasiere E, Rapetti R, Pirisi M. Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virus. Curr Opin Investig Drugs 2007; 8:150-158.
7. Stuyver LJ, McBrayer TR, Tharnish PM, et al. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2′-deoxy-2′- fluoro-2′-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother 2006; 17:79-87.
8. Murakami E, Bao H, Ramesh M, et al. Mechanism of activation of beta-D-2′-deoxy-2′-fluoro-2′-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother 2007; 51:503-509.
9. Reddy R, Rodriguez-Torres M, Gane E, et al. Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 2007; 46 Suppl 1:862A.
10. McHutchison JG, Reddy R, Rodriguez-Torres M, et al. Potent antiviral activity of the nucleoside HCV inhibitor, R7128, in prior IFN non-responders. Hep DART Frontiers in Drug Development for Viral Hepatitis. 9-13 December 2007, Lahaina, Hawaii, USA. Abstract 61.
11. th International Symposium on Hepatitis C Virus & Related Viruses. 9-13 September 2007, Glasgow, Scotland, UK. Abstract P-275.
12. Coelmont L, Paeshuyse J, Windisch MP, De Clercq E, Bartenschlager R, Neyts J. Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2′-C-methylcytidine, the active component of valopicitabine. Antimicrob Agents Chemother 2006; 50:3444-3446.
13. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-107.
14. Guo JT, Zhu Q, Seeger C. Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons. J Virol 2003; 77:10769-10779.
15. Eldrup AB, Allerson CR, Bennett CF, et al. Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J Med Chem 2004; 47:2283-2295.
16. Clark JL, Hollecker L, Mason JC, et al. Design, synthesis, and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J Med Chem 2005; 48:5504-5508.
17. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. Science 2000; 290:1972-1974.
18. Stuyver LJ, Whitaker T, McBrayer TR, et al. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother 2003; 47:244-254.
19. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
20. Belen'kii MS, Schinazi RF. Multiple drug effect analysis with confidence interval. Antiviral Res 1994; 25:1-11.
21. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58:621-681.
22. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492.
23. Zhang Y, Jamaluddin M, Wang S, et al. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol 2003; 77:5933-5947.
24. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436:967-972.
25. Lanford RE, Guerra B, Lee H, et al. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol 2003; 77:1092-1104.
26. Tanabe Y, Sakamoto N, Enomoto N, et al. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J Infect Dis 2004; 189:1129-1139.
27. Idenix Pharmaceuticals. Valopicitabine (NM283) produces greater suppression of HCV when added to pegylated interferon plus ribavirin (Updated 12 June 2007). Available from: http://www.hivandhepatitis.com/hep_c/news/2007/ 062207_b.html
28. Franciscus A. FDA: NM-283 on hold. HCV Advocate August 2007 vol 10, issue 8. Available from: http://www.hcvadvocate.org/news/newsLetter/2007/ advocate0807.html.
29. Hernandez-Santiago BI, Bassit L, Grier J, Schinazi RF. Anti-HCV activity and cellular pharmacology of 2′-methylcytidine alone and in combination with non-toxic concentrations of ribavirin in the HCV replicon system. Antivir Ther 2007; 12:S28.
30. Dieterish D, Lawitz E, Nguyen T, et al. Early clearance of HCV RNA with valopicitabine (NM283) plus PEG-Interferon in treatment-naive patients with HCV-1 infection: First results from a phase IIb trial. J Hepatol 2006 44 Suppl 2:S271-S272.
31. Stauber RE, Stadlbauer V. Novel approaches for therapy of chronic hepatitis C. J Clin Virol 2006; 36:87-94.